{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T00:25:15Z","timestamp":1795220715139,"version":"4.10.3"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"15","funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe (German Cancer Aid)","doi-asserted-by":"publisher","award":["70113009"],"award-info":[{"award-number":["70113009"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft (DFG)","doi-asserted-by":"publisher","award":["111724"],"award-info":[{"award-number":["111724"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Center for Molecular Medicine Cologne"},{"DOI":"10.13039\/501100003390","name":"Fritz Thyssen Stiftung (Fritz Thyssen Foundation)","doi-asserted-by":"publisher","award":["10.16.1.028MN"],"award-info":[{"award-number":["10.16.1.028MN"]}],"id":[{"id":"10.13039\/501100003390","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MKW North Rhine Westphalia","award":["1411ng005"],"award-info":[{"award-number":["1411ng005"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft (DFG)","doi-asserted-by":"publisher","award":["UL379\/1-1"],"award-info":[{"award-number":["UL379\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft (DFG)","doi-asserted-by":"publisher","award":["KFO-286 RP2\/CP1"],"award-info":[{"award-number":["KFO-286 RP2\/CP1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung (BMBF)","doi-asserted-by":"publisher","award":["SMOOSE 01ZX1303A"],"award-info":[{"award-number":["SMOOSE 01ZX1303A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MKW North Rhine Westphalia","award":["LS-1-1-030a"],"award-info":[{"award-number":["LS-1-1-030a"]}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung (EKFS)","doi-asserted-by":"publisher","award":["EKFS-2014-A06"],"award-info":[{"award-number":["EKFS-2014-A06"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Small cell lung cancer (SCLC) represents the most aggressive pulmonary neoplasm and is often diagnosed at late stage with limited survival, despite combined chemotherapies. We show in an autochthonous mouse model of SCLC that combined anti-VEGF\/anti-PD-L1\u2013targeted therapy synergistically improves treatment outcome compared with anti\u2013PD-L1 and anti-VEGF monotherapy. Mice treated with anti\u2013PD-L1 alone relapsed after 3 weeks and were associated with a tumor-associated PD-1\/TIM-3 double-positive exhausted T-cell phenotype. This exhausted T-cell phenotype upon PD-L1 blockade was abrogated by the addition of anti-VEGF\u2013targeted treatment. We confirmed a similar TIM-3\u2013positive T-cell phenotype in peripheral blood mononuclear cells of patients with SCLC with adaptive resistance to anti\u2013PD-1 treatment. Mechanistically, we show that VEGFA enhances coexpression of the inhibitory receptor TIM-3 on T cells, indicating an immunosuppressive function of VEGF in patients with SCLC during anti\u2013PD-1-targeted treatment. Our data strongly suggest that a combination of anti-VEGF and anti\u2013PD-L1 therapies can be an effective treatment strategy in patients with SCLC.<\/jats:p>\n                  <jats:p>Significance: Combining VEGF and PD-L1 blockade could be of therapeutic benefit to patients with small cell lung cancer. Cancer Res; 78(15); 4270\u201381. \u00a92018 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-17-2176","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T10:10:32Z","timestamp":1526638232000},"page":"4270-4281","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":166,"title":["Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer"],"prefix":"10.1158","volume":"78","author":[{"given":"Lydia","family":"Meder","sequence":"first","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"2Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schuldt","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"2Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2785-9726","authenticated-orcid":false,"given":"Martin","family":"Thelen","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"3Cologne Interventional Immunology, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schmitt","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Dietlein","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, Massachusetts."},{"name":"5Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts; US Institute for Pathology, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Klein","sequence":"additional","affiliation":[{"name":"6Institute for Pathology, University Hospital Cologne, Cologne, Germany."},{"name":"7Else Kr\u00f6ner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"2Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany."},{"name":"7Else Kr\u00f6ner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne, Cologne, Germany."},{"name":"8German Hodgkin Study Group, Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Wennhold","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"3Cologne Interventional Immunology, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacija","family":"Vlasic","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Oberbeck","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Riedel","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Florin","sequence":"additional","affiliation":[{"name":"6Institute for Pathology, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Golfmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"2Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans A.","family":"Schl\u00f6\u00dfer","sequence":"additional","affiliation":[{"name":"3Cologne Interventional Immunology, University Hospital Cologne, Cologne, Germany."},{"name":"9Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete","family":"Odenthal","sequence":"additional","affiliation":[{"name":"2Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany."},{"name":"6Institute for Pathology, University Hospital Cologne, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Buettner","sequence":"additional","affiliation":[{"name":"2Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany."},{"name":"6Institute for Pathology, University Hospital Cologne, Cologne, Germany."},{"name":"10Center for Integrated Oncology Cologne\/Bonn, University Hospital Cologne, Cologne; University Hospital Bonn, Bonn, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Wolf","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"10Center for Integrated Oncology Cologne\/Bonn, University Hospital Cologne, Cologne; University Hospital Bonn, Bonn, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"10Center for Integrated Oncology Cologne\/Bonn, University Hospital Cologne, Cologne; University Hospital Bonn, Bonn, Germany."},{"name":"11Cologne Excellence Cluster in Cellular Stress Responses and Aging-associated Disorders (CECAD), Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"2Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany."},{"name":"10Center for Integrated Oncology Cologne\/Bonn, University Hospital Cologne, Cologne; University Hospital Bonn, Bonn, Germany."},{"name":"11Cologne Excellence Cluster in Cellular Stress Responses and Aging-associated Disorders (CECAD), Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"3Cologne Interventional Immunology, University Hospital Cologne, Cologne, Germany."},{"name":"10Center for Integrated Oncology Cologne\/Bonn, University Hospital Cologne, Cologne; University Hospital Bonn, Bonn, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Christian","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"10Center for Integrated Oncology Cologne\/Bonn, University Hospital Cologne, Cologne; University Hospital Bonn, Bonn, Germany."},{"name":"11Cologne Excellence Cluster in Cellular Stress Responses and Aging-associated Disorders (CECAD), Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland T.","family":"Ullrich","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany."},{"name":"2Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany."},{"name":"10Center for Integrated Oncology Cologne\/Bonn, University Hospital Cologne, Cologne; University Hospital Bonn, Bonn, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"2022061700425253400_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2478\/v10019-012-0007-1","article-title":"Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting","volume":"46","author":"Lekic","year":"2012","journal-title":"Radiol Oncol"},{"key":"2022061700425253400_bib2","first-page":"S565","article-title":"Chemotherapy advances in small-cell lung cancer","volume":"5","author":"Chan","year":"2013","journal-title":"J Thorac Dis"},{"key":"2022061700425253400_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022061700425253400_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2022061700425253400_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"2022061700425253400_bib6","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1200\/JCO.2017.35.15_suppl.8569","article-title":"Small cell lung cancer: the immune microenvironment and prognostic impact of checkpoint expression. Presented Saturday, June 3 2017, ASCO","volume":"35","author":"Rivalland","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061700425253400_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2022061700425253400_bib8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"2022061700425253400_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061700425253400_bib10","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061700425253400_bib11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061700425253400_bib12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022061700425253400_bib13","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061700425253400_bib14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061700425253400_bib15","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies","volume":"69","author":"Ozao-Choy","year":"2009","journal-title":"Cancer Res"},{"key":"2022061700425253400_bib16","doi-asserted-by":"crossref","first-page":"492920","DOI":"10.1155\/2012\/492920","article-title":"Modulation of immunity by antiangiogenic molecules in cancer","volume":"2012","author":"Terme","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2022061700425253400_bib17","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061700425253400_bib18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"2022061700425253400_bib19","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-06-2450","article-title":"T-cell distribution and adhesion receptor expression in metastatic melanoma","volume":"13","author":"Weishaupt","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061700425253400_bib20","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy","volume":"178","author":"Bouzin","year":"2007","journal-title":"J Immunol"},{"key":"2022061700425253400_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2326-6066.CIR-16-0084","article-title":"VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma","volume":"4","author":"Wu","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2022061700425253400_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"2022061700425253400_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"2022061700425253400_bib24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"2022061700425253400_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lungcan.2004.03.006","article-title":"Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3","volume":"46","author":"Tanno","year":"2004","journal-title":"Lung Cancer"},{"key":"2022061700425253400_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Schultheis","year":"2015","journal-title":"Eur J Cancer"},{"key":"2022061700425253400_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","article-title":"Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model","volume":"4","author":"Meuwissen","year":"2003","journal-title":"Cancer Cell"},{"key":"2022061700425253400_bib28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/nprot.2009.95","article-title":"Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase","volume":"4","author":"DuPage","year":"2009","journal-title":"Nat Protoc"},{"key":"2022061700425253400_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2022061700425253400_bib30","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2022061700425253400_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"2022061700425253400_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"2022061700425253400_bib33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"key":"2022061700425253400_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061700425253400_bib35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"2022061700425253400_bib36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/gutjnl-2014-309094","article-title":"Tim-3 expression in tumour-associated macrophages: a new player in HCC progression","volume":"64","author":"Flecken","year":"2015","journal-title":"Gut"},{"key":"2022061700425253400_bib37","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022061700425253400_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","article-title":"Emerging Tim-3 functions in antimicrobial and tumor immunity","volume":"32","author":"Sakuishi","year":"2011","journal-title":"Trends Immunol"},{"key":"2022061700425253400_bib39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","article-title":"Tim-3: an emerging target in the cancer immunotherapy landscape","volume":"2","author":"Anderson","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2022061700425253400_bib40","doi-asserted-by":"crossref","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"2022061700425253400_bib41","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"2022061700425253400_bib42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res"},{"key":"2022061700425253400_bib43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature08629","article-title":"A small-cell lung cancer genome with complex signatures of tobacco exposure","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"key":"2022061700425253400_bib44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2022061700425253400_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"2022061700425253400_bib46","doi-asserted-by":"crossref","first-page":"pii: eaak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"2022061700425253400_bib47","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"2022061700425253400_bib48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"key":"2022061700425253400_bib49","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1158\/1078-0432.CCR-17-0647","article-title":"Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression","volume":"23","author":"Dalton","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061700425253400_bib50","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.celrep.2015.03.055","article-title":"Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy","volume":"11","author":"Rivera","year":"2015","journal-title":"Cell Rep"},{"key":"2022061700425253400_bib51","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","article-title":"Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells","volume":"160","author":"Oyama","year":"1998","journal-title":"J Immunol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/15\/4270\/2603361\/4270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/15\/4270\/2603361\/4270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T14:26:00Z","timestamp":1693664760000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/78\/15\/4270\/543855\/Combined-VEGF-and-PD-L1-Blockade-Displays"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":51,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2018,7,31]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-17-2176","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22411914","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22411914.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22411920","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22411920.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6508329.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6508329","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]}}}